Summit Therapeutics shareholders elect 8 directors and approve auditor and advisory compensation

Summit Therapeutics Inc.

All 8 director nominees elected with >602M votes for each; broker non-votes ~24.1M.
Ratification of PwC as auditor for FY2023 approved: 626.2M for, 24.7K against.
Advisory vote on executive compensation approved: 601.0M for, 653.1K against, 472.6K abstentions.
Meeting held May 23, 2023; all proposals received required stockholder approval.

item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Summit Therapeutics Inc. shareholders approved Election of Directors at the 2023-05-23 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-23

Exact text from the filing

Proposal 1 Election of Directors Director Nominees For Withheld Broker Non-Votes Robert W. Duggan 602,091,126 82,492 24,127,917 Mahkam Zanganeh 602,109,288 64,330 24,127,917 Kenneth A. Clark 602,090,958 82,660 24,127,917 Robert Booth 602,090,089 83,529 24,127,917 Ujwala Mahatme 602,089,139 84,479 24,127,917 Manmeet S. Soni 602,035,379 138,239 24,127,917 Alessandra Cesano 602,081,213 92,405 24,127,917 Yu Xia 602,011,269 162,349 24,127,917

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Summit Therapeutics Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-05-23 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-23

Exact text from the filing

Proposal 3 For Against Abstain Broker Non-Votes Advisory vote on compensation of named executive officers 601,047,918 653,118 472,582 24,127,917

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Summit Therapeutics Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP, United States as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-23 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-23

Exact text from the filing

Proposal 2 For Against Abstain Broker Non-Votes Ratification of the appointment of PricewaterhouseCoopers LLP, United States 626,187,678 24,729 89,128 —

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001599298-23-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.